Not just yet. Allow the time for the P2 trials' data to come in. If solid, viability/marketability are proven and inherent Co value drastically increased.
Sell then. For a much higher multiple. I feel that a larger PH would buy P based upon good P2b data, but snatch up the whole Co (K and B) at a discount as the other compounds remain unproven (mostly).
What boggles my mind is that the market at large seems to have forgotten the Dapto comparison of B....